Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — Q1 2027 Earnings Presentation
17 slides from Atomo Diagnostics's earnings presentation, Oct 29, 2026
Slide 1: 1Q 2027 Results Overview
rsonal use only ATOMO DIAGNOSTICS 1Q 2027 RESULTS OVERVIEW 29 OCTOBER 2026 1
Slide 2: Disclaimer
DISCLAIMER ASX: AT1 This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on The information presented in this presentation is subject to change without notice and Atomo does rsonal use only information available as at the date of this presentation. The information in this
Slide 3: Quarterly Highlights
ATOMO DIAGNOSTICS – 1Q27 ASX: AT1 Transitioning to sustainable revenue growth with an expanding new product pipeline Quarterly Highlights rsonal use only PIPELINE MILESTONES COMMERCIAL PERFORMANCE Upfront Diagnostics + Atomo partnership Next-generation rapid Pre-Hospital LVTWO Brain Disease Test. $1
Slide 4: HIV Q1 Revenue Performance
HIV Q1 REVENUE PERFORMANCE ASX: AT1 ASX: AT1 Global sales growth in HIV franchise led by International supply and ANZ pharmacy channels rsonal use only Q1 PERFORMANCE WHERE Q1 SALES CAME FROM HIV SALES GROWTH | YOY INTERNATIONAL | VIATRIS Increased HIV test supply to Viatris Healthcare (Pty) Ltd thr
Slide 5: Pascal OEM Q1 Revenue Performance
PASCAL OEM Q1 REVENUE PERFORMANCE ASX: AT1 Strong QOQ growth driven by Lumos Diagnostics’ FebriDx rsonal use only ATOMO OEM PERFORMANCE | Q1 Q-ON-Q US FEBRIDX® ADOPTION | LUMOS-REPORTED +469% +713% 215 LIVE US SITES September 2026 OEM SALES REVENUE GROWTH IN DEVICES SUPPLIED A$165k → A$939k +26.5% 1
Slide 6: Gen 4 HIV Partnership Opens a New Commercial Path
GEN 4 HIV PARTNERSHIP OPENS A NEW COMMERCIAL PATH ASX: AT1 ASX: AT1 Global licence, development and supply agreement with Innovation Scientific WHO DOES WHAT COMMERCIAL PATH rsonal use only INNOVATION SCIENTIFIC 18 MONTHS THE MOU AGREEMENT — Complete final assay development Planned IVDR and TGA regi
Slide 7: HIV Rapid Testing Market: Gen 3 and Gen 4
HIV RAPID TESTING MARKET: GEN 4 and GEN 3 ASX: AT1 ASX: AT1 Large and growing market opportunity for Atomo’s expanding HIV franchise rsonal use only GEN 3 | ESTABLISHED - SELF-TEST GEN 4 | NEW PRODUCT - PROFESSIONAL TEST FORMAT Antibody-based HIV self-test FORMAT Proposed rapid antigen/antibody test
Slide 8: Upfront + Atomo Partner on Next-Generation Test
UPFRONT + ATOMO PARTNER ON NEXT-GENERATION TEST ASX: AT1 ASX: AT1 Upfront’s biomarker assay moves into Atomo’s technology platform rsonal use only PARTNERSHIP ANNOUNCEMENT Atomo and Upfront announce partnership for Upfront’s next-generation test in Atomo’s device. DETECT DEPLOY DECIDE EARLIER LVTwo
Slide 9: Brain Disease Burden Creates a Scalable Triage Opportunity
BRAIN DISEASE BURDEN CREATES A SCALABLE TRIAGE OPPORTUNITY ASX: AT1 ASX: AT1 The partnership will provide a new revenue stream for a significant and exciting new clinical indications GLOBAL CLINICAL NEED REGIONAL MARKETS rsonal use only 11.9 million 54,800 1.46m 795,000+ AUSTRALIA + NEW EUROPE UNITE
Slide 10: Active Syphilis Transfers to Manufacturing
ACTIVE SYPHILIS TRANSFERS TO MANUFACTURING ASX: AT1 Program remains on schedule, with regulator engagement beginning and launch targeted within 18–24 months TEST DIFFERENTIATION EARLY CLINICAL PERFORMANCE rsonal use only 15 MINUTES 100% SENSITIVITY against active syphilis samples by clinical history
Slide 11: Atomo Proprietary Product Pipeline
ATOMO PROPRIETARY PRODUCT PIPELINE ASX: AT1 ASX: AT1 Commercial products fund a broader portfolio progressing through validation, development and feasibility rsonal use only PRODUCT / APPLICATION FEASIBILITY DEVELOPMENT VALIDATION COMMERCIAL HIV GEN 3 HIV screening / self-test COMMERCIAL ACTIVE SYPH
Slide 12: OEM Partner Pipeline
OEM PARTNER PIPELINE ASX: AT1 ASX: AT1 Atomo technology enables partner assays to move from technical validation into commercial supply at scale PRODUCT / APPLICATION FEASIBILITY DEVELOPMENT VALIDATION COMMERCIAL rsonal use only FEBRIDX® Lumos · acute respiratory infection COMMERCIAL PREGNANCY NG Bi
Slide 13: 1Q27 – Profit & Loss
1Q27 – PROFIT & LOSS Revenue and gross profit increased strongly year-on-year REVENUE A$'000 1Q FY27 1Q FY26 YoY change $1.63m rsonal use only 1Q FY26 $0.68m Revenue 1,628 680 +140% +140% YoY Cost of sales (1,204) (424) +184% cost GROSS PROFIT Gross profit 424 256 +66% $0.42m 1Q FY26 $0.26m Gross ma
Slide 14: 1Q27 – Balance Sheet
1Q27 – BALANCE SHEET 1Q FY27 closes with $2.67m in cash, $9.63m in assets and no bank debt A$'000 1Q FY27 CASH rsonal use only Cash and cash equivalents 2,669 Trade and other receivables 1,301 $2.67m Inventories 1,723 available liquidity R&D tax rebate receivable 1,075 Prepayments 327 TOTAL ASSETS T
Slide 15: 1Q27 – Cash Flow
1Q27 – CASH FLOW Q1 FY27 ended with $2.67m in cash after a $1.01m net cash outflow A$'000 Q1 FY27 rsonal use only Receipts from customers 2,401 Payments to suppliers and employees (3,437) Interest received 23 CASH AT END Grant funds received from CRC-P 84 Net cash used in operating activities (929)
Slide 16: Building a Stronger Base for Scalable Growth
BUILDING A STRONGER BASE FOR SCALABLE GROWTH Commercial momentum is funding a broader product pipeline and a more diversified revenue base rsonal use only HIV FRANCHISE LEADS COMMERCIAL TRACTION $1.63m HIV sales increased 38.3% year on year, led by international supply and ANZ pharmacy channels. 1Q
Slide 17: Q1 FY27 Quarterly Investor Webinar
Atomo Q1 FY27 Quarterly Investor Webinar Presentation : AT1 Atomo Diagnostics Limited will hold its Q1 FY27 Quarterly Investor Webinar on Tuesday 03rd November rsonal use only 2026 at 2pm (AEDT). To access the webinar, please pre-register by clicking this link To access Atomo’s Investor Hub, please